Growth hormone therapy is associated with improved uterine dimensions in girls with Turner syndrome prior to oestrogen replacement
Clinical Endocrinology · 2024
DOI: 10.1111/cen.14957 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Sunetra Mondal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India. Hauptthemen laut MEDLINE: Human Growth Hormone, Turner Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Adult women with Turner syndrome (TS) have high rates of miscarriage, presumably due to the abnormal size and shape of the uterus. There is a paucity of data regarding the determinants of uterine volume (UtVol) in young girls with TS before the initiation of oestrogen replacement therapy (ERT).
Methods
We performed a cross‐sectional study on premenarchal girls with TS, aged 5–15 years, pubertal stage B1–B3, not having received ERT ( n = 73) and 50 age‐matched healthy controls. Anthropometric parameters and a history of growth hormone (GH) therapy (≥1 year) were noted. Uterine length (UtL), UtVol, and mean‐ovarian‐volume (MOV) standard‐deviation scores (SDS) were determined from transabdominal ultrasonography data.
Results
Girls with TS had lower median UtVol‐SDS (−1.07 vs. 0.86; p < .001), UtL‐SDS (−3.72 vs. −0.41; p < .001) and MOV‐SDS (−5.53 vs. 1.96; p < .001) compared to age‐matched controls. Among TS girls, recipients of GH ( n = 38) had higher UtVol‐SDS (−0.63 vs. −1.39; p = .0001), UtL‐SDS (−1.73 vs. −6.49; p < .0001) but similar MOV‐SDS compared to nonrecipients ( n = 35). Those with normal uterine volume for age (NUVA, n = 29) had earlier initiation (7.8 vs. 9.3 years; p = .03) and a longer duration of GH (3.71 vs. 2.14 years; p = .002) than those with low UtVol for age ( n = 44). UtVol‐SDS correlated with duration of GH ( ρ = 0.411, p = .01) and negatively with age at GH initiation ( ρ = −0.479, p = .003). In a model adjusted for pubertal status, karyotype and height‐SDS, GH use could independently predict having NUVA (odds ratio: 5.09, confidence interval: 1.63–15.94, p = .005).
Conclusion
GH therapy has a stimulatory effect on uterine dimensions in pre‐and peripubertal girls with TS. Earlier initiation and longer duration of GH is important in TS girls before ERT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
- Department of Endocrinology, JSS Medical College and Hospital, JSS Academy of Higher Education and Research, Mysore, Karnataka, India.
- Department of Radiology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
- Healthworld Hospitals, Durgapur, West Bengal, India.
ORCID-Profile: Sunetra Mondal
Zitieren
APA
Mondal, S., Gargari, P., Nagendra, L., Mandal, S., Kumar, R. C., Shah, P., Haldar, M., Chowdhury, S., & Mukhopadhyay, S. (2024). Growth hormone therapy is associated with improved uterine dimensions in girls with Turner syndrome prior to oestrogen replacement. Clinical Endocrinology. https://doi.org/10.1111/cen.14957
Vancouver
Mondal S, Gargari P, Nagendra L, Mandal S, Kumar RC, Shah P, et al. Growth hormone therapy is associated with improved uterine dimensions in girls with Turner syndrome prior to oestrogen replacement. Clinical Endocrinology. 2024. doi:10.1111/cen.14957
BibTeX
@article{Mondal2024,
author = {Mondal, Sunetra and Gargari, Piyas and Nagendra, Lakshmi and Mandal, Santanu and Kumar, Rathin C and Shah, Pooja and Haldar, Mandira and Chowdhury, Subhankar and Mukhopadhyay, Satinath},
title = {Growth hormone therapy is associated with improved uterine dimensions in girls with Turner syndrome prior to oestrogen replacement},
journal = {Clinical Endocrinology},
year = {2024},
doi = {10.1111/cen.14957}
}
EUVIMED